{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:22:21Z","timestamp":1793715741714,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To report on five-year results with the PreserFlo MicroShunt (MicroShunt) for the surgical treatment of open-angle glaucoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Retrospective case series of consecutive patients who underwent a stand-alone MicroShunt implantation at the University Eye Clinic of Maastricht. If a patient underwent the procedure in both eyes, only the first eye was included in the analysis. MicroShunt implantation was augmented with 0.2\u2009mg\/ml mitomycin-C. The primary outcome was intraocular pressure (IOP) during follow-up. Furthermore, information on IOP-lowering medication use, success rates, reoperation rates, and postoperative complications was collected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixty-six eyes were included for analyses. Diagnoses included primary open-angle glaucoma (88%) and pigmentary glaucoma (12%). The majority of patients had moderate or advanced glaucoma, based on the mean deviation of the visual field examination. Mean (95% - confidence interval) IOP dropped from 21.8 (20.8\u201322.8) at baseline to 13.2 (11.8\u201314.6) mmHg after 5 years (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Mean number of IOP-lowering medications was reduced from 2.5 (2.2\u20132.9) at baseline to 0.9 (0.5\u20131.2), 1.0 (0.7\u20131.4), and 1.1 (0.7\u20131.5) after three, four, and five years (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Needling or surgical revision was performed in twelve eyes (18%). Nineteen eyes (29%) required further IOP-lowering surgery. Postoperative complications were usually mild and self-limiting and included early hypotony, shallow anterior chamber, and hyphaema.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>After five years, the MicroShunt was found to be a safe procedure, leading to a sustained reduction in mean IOP and number of IOP-lowering medications. However, almost one third of the eyes required further IOP-lowering interventions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03707-3","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T19:05:46Z","timestamp":1740078346000},"page":"1540-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Five-year follow-up with the PreserFlo MicroShunt for open-angle glaucoma"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0262-0540","authenticated-orcid":false,"given":"Lotte M. J.","family":"Scheres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Kujovic-Aleksov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Winkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M. P. C.","family":"de Crom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carroll A. B.","family":"Webers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-1426","authenticated-orcid":false,"given":"Henny J. M.","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"3707_CR1","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105:1.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"3707_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000458483","volume":"59","author":"PT Khaw","year":"2017","unstructured":"Khaw PT, Chiang M, Shah P, Sii F, Lockwood A, Khalili A. EnHANCED TRABECULectomy: The Moorfields safer surgery system. Dev Ophthalmol. 2017;59:15\u201335.","journal-title":"Dev Ophthalmol"},{"key":"3707_CR3","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.ophtha.2013.07.049","volume":"120","author":"JF Kirwan","year":"2013","unstructured":"Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway DC, King AJ, et al. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology. 2013;120:2532\u20139.","journal-title":"Ophthalmology"},{"key":"3707_CR4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ajo.2011.10.024","volume":"153","author":"SJ Gedde","year":"2012","unstructured":"Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153:804\u201314.e1.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ceo.12846","volume":"45","author":"I Rodriguez-Una","year":"2017","unstructured":"Rodriguez-Una I, Azuara-Blanco A, King AJ. Survey of glaucoma surgical preferences and post-operative care in the United Kingdom. Clin Exp Ophthalmol. 2017;45:232\u201340.","journal-title":"Clin Exp Ophthalmol"},{"key":"3707_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0002-9394(68)91288-9","volume":"66","author":"JE Cairns","year":"1968","unstructured":"Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66:673\u20139.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbm.b.33525","volume":"105","author":"L Pinchuk","year":"2017","unstructured":"Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, et al. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017;105:211\u201321.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"3707_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/ICU.0b013e32835cf0f5","volume":"24","author":"SJ Gedde","year":"2013","unstructured":"Gedde SJ, Panarelli JF, Banitt MR, Lee RK. Evidenced-based comparison of aqueous shunts. Curr Opin Ophthalmol. 2013;24:87\u201395.","journal-title":"Curr Opin Ophthalmol."},{"key":"3707_CR9","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1001\/archopht.124.12.1742","volume":"124","author":"AC Acosta","year":"2006","unstructured":"Acosta AC, Espana EM, Yamamoto H, Davis S, Pinchuk L, Weber BA, et al. A Newly Designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): biocompatibility and function in normal rabbit eyes. Arch Ophthalmol. 2006;124:1742\u20139.","journal-title":"Arch Ophthalmol"},{"key":"3707_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ogla.2021.07.008","volume":"5","author":"HJM Beckers","year":"2022","unstructured":"Beckers HJM, Aptel F, Webers CAB, Bluwol E, Mart\u00ednez-de-la-Casa JM, Garc\u00eda-Feijo\u00f3 J, et al. Safety and Effectiveness of the PRESERFLO\u00ae MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study. Ophthalmol Glaucoma. 2022;5:195\u2013209.","journal-title":"Ophthalmol Glaucoma"},{"key":"3707_CR11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ophtha.2023.09.023","volume":"131","author":"JF Panarelli","year":"2024","unstructured":"Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study. Ophthalmology. 2024;131:266\u201376.","journal-title":"Ophthalmology."},{"key":"3707_CR12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajo.2020.02.020","volume":"215","author":"MB Schlenker","year":"2020","unstructured":"Schlenker MB, Durr GM, Michaelov E, Ahmed IIK. Intermediate outcomes of a novel standalone ab externo SIBS MicroShunt with mitomycin C. Am J Ophthalmol. 2020;215:141\u201353.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ogla.2021.08.005","volume":"5","author":"AM Fea","year":"2022","unstructured":"Fea AM, Laffi GL, Martini E, Economou MA, Caselgrandi P, Sacchi M, et al. Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma: a retrospective European multicenter study. Ophthalmol Glaucoma. 2022;5:210\u20138.","journal-title":"Ophthalmol Glaucoma"},{"key":"3707_CR14","doi-asserted-by":"crossref","first-page":"e0256670","DOI":"10.1371\/journal.pone.0256670","volume":"16","author":"M Nobl","year":"2021","unstructured":"Nobl M, Freissinger S, Kassumeh S, Priglinger S, Mackert MJ. One-year outcomes of microshunt implantation in pseudoexfoliation glaucoma. PloS one. 2021;16:e0256670\u2013e.","journal-title":"PloS one"},{"key":"3707_CR15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/IJG.0000000000002178","volume":"32","author":"AM Seuthe","year":"2023","unstructured":"Seuthe AM, Erokhina M, Szurman P, Haus A. One year results of the Preserflo MicroShunt implantation for refractory glaucoma. J Glaucoma. 2023;32:414\u20139.","journal-title":"J Glaucoma"},{"key":"3707_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bjophthalmol-2020-317299","volume":"106","author":"GM Durr","year":"2022","unstructured":"Durr GM, Schlenker MB, Samet S, Ahmed IIK. One-year outcomes of stand-alone ab externo SIBS microshunt implantation in refractory glaucoma. Br J Ophthalmol. 2022;106:71\u20139.","journal-title":"Br J Ophthalmol"},{"key":"3707_CR17","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.ophtha.2021.05.023","volume":"128","author":"ND Baker","year":"2021","unstructured":"Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, et al. Ab-Externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128:1710\u201321.","journal-title":"Ophthalmology"},{"key":"3707_CR18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/IJG.0000000000001734","volume":"30","author":"JF Batlle","year":"2021","unstructured":"Batlle JF, Corona A, Albuquerque R. Long-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study. J Glaucoma. 2021;30:281\u20136.","journal-title":"J Glaucoma"},{"key":"3707_CR19","first-page":"e433","volume":"99","author":"LMJ Scheres","year":"2021","unstructured":"Scheres LMJ, Kujovic-Aleksov S, Ramdas WD, de Crom RMPC, Roelofs LCG. Berendschot TTJM, et al. XEN\u00ae Gel Stent compared to PRESERFLO\u2122 MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol. 2021;99:e433\u201340.","journal-title":"Acta Ophthalmol"},{"key":"3707_CR20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1034\/j.1600-0420.1999.770613.x","volume":"77","author":"J Siderov","year":"1999","unstructured":"Siderov J, Tiu AL. Variability of measurements of visual acuity in a large eye clinic. Acta Ophthalmol Scand. 1999;77:673\u20136.","journal-title":"Acta Ophthalmol Scand"},{"key":"3707_CR21","volume-title":"WGA guidelines on design and reporting of glaucoma surgical trials","author":"T Shaarawy","year":"2009","unstructured":"Shaarawy T, Grehn F, Sherwood M, World Glaucoma Association. WGA guidelines on design and reporting of glaucoma surgical trials. The Hague: Kugler Publications; 2009."},{"key":"3707_CR22","doi-asserted-by":"crossref","unstructured":"Tanner A, Haddad F, Fajardo-Sanchez J, Nguyen E, Thong KX, Ah-Moye S, et al. One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis. Br J Ophthalmol. 2022:bjophthalmol-2021-320631.","DOI":"10.1136\/bjophthalmol-2021-320631"},{"key":"3707_CR23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ogla.2023.04.002","volume":"6","author":"JJ Armstrong","year":"2023","unstructured":"Armstrong JJ, De Francesco T, Ma J, Schlenker MB, Ahmed IIK. Ab externo SIBS microshunt with mitomycin C for open-angle glaucoma: three-year results as a primary surgical intervention. Ophthalmol Glaucoma. 2023;6:480\u201392.","journal-title":"Ophthalmol Glaucoma"},{"key":"3707_CR24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ogla.2022.11.006","volume":"6","author":"L Van Lancker","year":"2023","unstructured":"Van Lancker L, Saravanan A, Abu-Bakra M, Reid K, Quijano C, Goyal S, et al. Clinical outcomes and cost analysis of PreserFlo versus trabeculectomy for glaucoma management in the United Kingdom. Ophthalmol Glaucoma. 2023;6:342\u201357.","journal-title":"Ophthalmol Glaucoma"},{"key":"3707_CR25","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/IJG.0000000000000368","volume":"25","author":"JF Batlle","year":"2016","unstructured":"Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP, et al. Three-year follow-up of a novel aqueous humor MicroShunt. J Glaucoma. 2016;25:e58\u201365.","journal-title":"J Glaucoma"},{"key":"3707_CR26","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s40123-024-00902-5","volume":"13","author":"AP Khawaja","year":"2024","unstructured":"Khawaja AP, Abeg\u00e3o Pinto L, Stalmans I, Aptel F, Barkander A, Barton K, et al. Additional guidance on the use of the PRESERFLO\u2122 MicroShunt in the treatment of glaucoma: insights from a Second Delphi Consensus Panel. Ophthalmol Ther. 2024;13:1569\u201388.","journal-title":"Ophthalmol Ther"},{"key":"3707_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ajo.2011.10.026","volume":"153","author":"SJ Gedde","year":"2012","unstructured":"Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153:789\u2013803.e2.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/ceo.13463","volume":"47","author":"M Lenzhofer","year":"2019","unstructured":"Lenzhofer M, Kersten-Gomez I, Sheybani A, Gulamhusein H, Strohmaier C, Hohensinn M, et al. Four-year results of a minimally invasive transscleral glaucoma gel stent implantation in a prospective multi-centre study. Clin Exp Ophthalmol. 2019;47:581\u20137.","journal-title":"Clin Exp Ophthalmol"},{"key":"3707_CR29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00417-002-0621-5","volume":"241","author":"HJ Beckers","year":"2003","unstructured":"Beckers HJ, Kinders KC, Webers CA. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol. 2003;241:106\u201310.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3707_CR30","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1097\/IJG.0000000000001848","volume":"30","author":"L Michaels","year":"2021","unstructured":"Michaels L, Holland L, Mercieca K. Trans-conjunctival erosion of a novel SIBS microshunt after revision surgery using mitomycin C. J Glaucoma. 2021;30:e349\u2013e51.","journal-title":"J Glaucoma"},{"key":"3707_CR31","volume":"25","author":"ET Fahy","year":"2022","unstructured":"Fahy ET, Ho H, Dukht U, Garg A, Lim KS. Conjunctival erosion following a PRESERFLO\u00ae MicroShunt procedure. Am J Ophthalmol Case Rep. 2022;25:101347.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3707_CR32","volume":"25","author":"C Chamard","year":"2022","unstructured":"Chamard C, Hammoud S, Bluwol E, Lachkar Y. Endothelial cell loss 5 years after Preserflo MicroShunt implantation: about two cases. Am J Ophthalmol Case Rep. 2022;25:101238.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3707_CR33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40123-021-00428-0","volume":"11","author":"M Ibarz-Barber\u00e1","year":"2022","unstructured":"Ibarz-Barber\u00e1 M, Morales-Fern\u00e1ndez L, Corroto-Cuadrado A, Martinez-Gald\u00f3n F, Ta\u00f1\u00e1-Rivero P, G\u00f3mez de Lia\u00f1o R, et al. Corneal endothelial cell loss after PRESERFLO\u2122 MicroShunt implantation in the anterior chamber: anterior segment OCT tube location as a risk factor. Ophthalmol Ther. 2022;11:293\u2013310.","journal-title":"Ophthalmol Ther"},{"key":"3707_CR34","first-page":"CD002897","volume":"2005","author":"M Wilkins","year":"2005","unstructured":"Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;2005:CD002897.","journal-title":"Cochrane Database Syst Rev"},{"key":"3707_CR35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0161-6420(02)01739-6","volume":"110","author":"C-Y Hu","year":"2003","unstructured":"Hu C-Y, Matsuo H, Tomita G, Suzuki Y, Araie M, Shirato S, et al. Clinical characteristics and leakage of functioning blebs after trabeculectomy with mitomycin-C in primary glaucoma patients. Ophthalmology. 2003;110:345\u201352.","journal-title":"Ophthalmology"},{"key":"3707_CR36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IJG.0000000000000720","volume":"26","author":"K Vinod","year":"2017","unstructured":"Vinod K, Gedde SJ, Feuer WJ, Panarelli JF, Chang TC, Chen PP, et al. 2nd. Practice preferences for glaucoma surgery: a survey of the American Glaucoma Society. J Glaucoma. 2017;26:687\u201393.","journal-title":"J Glaucoma"},{"key":"3707_CR37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ajo.2023.06.009","volume":"255","author":"MB Schlenker","year":"2023","unstructured":"Schlenker MB, Armstrong JJ, De Francesco T, Ahmed IIK. All Consecutive Ab Externo SIBS Microshunt implantations with mitomycin c: one-year outcomes and risk factors for failure. Am J Ophthalmol. 2023;255:125\u201340.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR38","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/bjophthalmol-2018-312972","volume":"103","author":"RG Mathew","year":"2019","unstructured":"Mathew RG, Parvizi S, Murdoch IE. Success of trabeculectomy surgery in relation to cataract surgery: 5-year outcomes. Br J Ophthalmol. 2019;103:1395.","journal-title":"Br J Ophthalmol"},{"key":"3707_CR39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ceo.12254","volume":"42","author":"DQ Nguyen","year":"2014","unstructured":"Nguyen DQ, Niyadurupola N, Tapp RJ, O\u2019Connell RA, Coote MA, Crowston JG. Effect of phacoemulsification on trabeculectomy function. Clin Exp Ophthalmol. 2014;42:433\u20139.","journal-title":"Clin Exp Ophthalmol"},{"key":"3707_CR40","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s40123-022-00529-4","volume":"11","author":"AP Khawaja","year":"2022","unstructured":"Khawaja AP, Stalmans I, Aptel F, Barton K, Beckers H, Klink T, et al. Expert Consensus on the Use of the PRESERFLO\u2122 MicroShunt device in the treatment of glaucoma: a modified Delphi Panel. Ophthalmol Ther. 2022;11:1743\u201366.","journal-title":"Ophthalmol Ther"},{"key":"3707_CR41","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archopht.119.12.1771","volume":"119","author":"Investigators TA","year":"2001","unstructured":"Investigators TA. The Advanced Glaucoma Intervention Study, 8: Risk of Cataract Formation After Trabeculectomy. Arch Ophthalmol. 2001;119:1771\u20139.","journal-title":"Arch Ophthalmol"},{"key":"3707_CR42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajo.2015.11.023","volume":"163","author":"DL Budenz","year":"2016","unstructured":"Budenz DL, Feuer WJ, Barton K, Schiffman J, Costa VP, Godfrey DG, et al. Postoperative complications in the Ahmed Baerveldt comparison study during five years of follow-up. Am J Ophthalmol. 2016;163:75\u201382.e3.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0002-9394(02)01919-0","volume":"135","author":"C Hylton","year":"2003","unstructured":"Hylton C, Congdon N, Friedman D, Kempen J, Quigley H, Bass E, et al. Cataract after glaucoma filtration surgery. Am J Ophthalmol. 2003;135:231\u20132.","journal-title":"Am J Ophthalmol"},{"key":"3707_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/ICU.0b013e32834ff1e7","volume":"23","author":"H Saheb","year":"2012","unstructured":"Saheb H, Ahmed IIK. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96\u2013104.","journal-title":"Curr Opin Ophthalmol"},{"key":"3707_CR45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/archophthalmol.2011.182","volume":"129","author":"BA Francis","year":"2011","unstructured":"Francis BA, Hong B, Winarko J, Kawji S, Dustin L, Chopra V. Vision loss and recovery after trabeculectomy: risk and associated risk factors. Arch Ophthalmol. 2011;129:1011\u20137.","journal-title":"Arch Ophthalmol"},{"key":"3707_CR46","volume":"23","author":"LMJ Scheres","year":"2023","unstructured":"Scheres LMJ, van den Biggelaar F, Winkens B, Kujovic-Aleksov S, M\u00fcskens R, de Waard PWT, et al. Effectiveness and cost-effectiveness of MicroShunt implantation versus standard trabeculectomy for open-angle glaucoma (a SIGHT study): study protocol of a multicentre randomised controlled trial. BMC Ophthalmol. 2023;23:43.","journal-title":"BMC Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03707-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03707-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03707-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:25:41Z","timestamp":1747657541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03707-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03707-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial Disclosures: LS, SK, and BW (none); RC: Consultant\u2014Abbvie, Iridex, Th\u00e9a Pharma; Lectures\u2014Iridex, Santen Pharmaceutical Co. Ltd, Th\u00e9a Pharma, Tramedico; CW: Consultant\u2014Novartis, Th\u00e9a Pharma; Support\u2014Novartis, Santen Pharmaceutical Co. Ltd; HB: Consultant\u2014InnFocus Inc. (a Santen Pharmaceutical Co. Ltd. company), Santen Pharmaceutical Co. Ltd, Glaukos, Abbvie, Novartis, Th\u00e9a Pharma, Elios, Nova Eye Medical; Research support\u2014InnFocus Inc. (a Santen Pharmaceutical Co. Ltd. company); Investment interest: Peyeoneer Medtech B.V.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}